Drugs moving into the clinic: 35
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| Synta Pharmaceuticals | STA-9090 | Oncology | " heat shock protein 90 (Hsp90) inhibitor unrelated to geldanamycin or its family of related compounds, such as 17-AAG" |
| Lexicon Pharmaceuticals | LX2931 | Rheumatoid arthritis and other autoimmune disorders | "Inhibits key enzyme in sphingolipid pathway, which controls lymphocyte circulation and trafficking to peripheral sites in the body during an inflammatory response. N.B. IND submitted to US FDA" |
| Trubion Pharamceuticals | TRU-016 | Oncology - B-cell malignancies: non-Hodgkin's lymphoma and chronic lymphocytic leukaemia (CLL) | "Depletes B cells by binding to a cell surface protein found in high-levels exclusively on B cells and to a lesser extent on a subpopulation of T cells and myeloid cells. The precise function of the target is not known, though experiments suggest that it plays an important role in B-cell regulation.N.B. IND submitted to US FDA" |
| Lundbeck | Lu AA47070 | Parkinson's disease and other neurological disorders | adenosine receptor inhibitor |
| Metastatix | MSX-122 | Oncology | CXCR4 inhibitor |
